CHB Investment Group LLC Purchases New Position in Axon Enterprise, Inc. (NASDAQ:AXON)

CHB Investment Group LLC purchased a new position in Axon Enterprise, Inc. (NASDAQ:AXON - Free Report) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 9,075 shares of the biotechnology company's stock, valued at approximately $3,626,000. Axon Enterprise makes up 1.9% of CHB Investment Group LLC's portfolio, making the stock its 5th largest position.

Other large investors also recently added to or reduced their stakes in the company. Quent Capital LLC raised its stake in shares of Axon Enterprise by 1,875.0% in the third quarter. Quent Capital LLC now owns 79 shares of the biotechnology company's stock valued at $32,000 after acquiring an additional 75 shares during the period. Blue Trust Inc. lifted its stake in Axon Enterprise by 987.5% in the second quarter. Blue Trust Inc. now owns 87 shares of the biotechnology company's stock worth $27,000 after purchasing an additional 79 shares during the last quarter. Trivant Custom Portfolio Group LLC bought a new stake in Axon Enterprise in the first quarter worth about $31,000. First PREMIER Bank purchased a new position in shares of Axon Enterprise during the first quarter valued at approximately $33,000. Finally, Asset Dedication LLC bought a new position in shares of Axon Enterprise during the second quarter valued at approximately $47,000. 79.08% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on AXON shares. JMP Securities boosted their price objective on Axon Enterprise from $375.00 to $430.00 and gave the company an "outperform" rating in a report on Thursday, September 12th. Northland Securities raised their price target on shares of Axon Enterprise from $330.00 to $365.00 and gave the stock an "outperform" rating in a research note on Thursday, August 8th. Needham & Company LLC reissued a "buy" rating and issued a $400.00 price objective on shares of Axon Enterprise in a research report on Wednesday, August 7th. Jefferies Financial Group initiated coverage on shares of Axon Enterprise in a research report on Wednesday, July 17th. They set a "buy" rating and a $385.00 target price on the stock. Finally, Bank of America assumed coverage on shares of Axon Enterprise in a research note on Wednesday, July 17th. They set a "buy" rating and a $380.00 price target for the company. Two analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $365.38.

Axon Enterprise Stock Up 0.8 %

Shares of NASDAQ:AXON traded up $3.57 during trading on Friday, reaching $438.05. The stock had a trading volume of 228,561 shares, compared to its average volume of 521,796. The company has a current ratio of 2.88, a quick ratio of 2.52 and a debt-to-equity ratio of 0.35. The company has a market capitalization of $33.10 billion, a P/E ratio of 115.58, a PEG ratio of 11.74 and a beta of 0.94. The firm's 50-day simple moving average is $388.71 and its 200 day simple moving average is $331.64. Axon Enterprise, Inc. has a one year low of $199.29 and a one year high of $440.89.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last issued its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported $1.20 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.02 by $0.18. The business had revenue of $504.00 million for the quarter, compared to the consensus estimate of $478.35 million. Axon Enterprise had a return on equity of 9.34% and a net margin of 16.06%. The business's quarterly revenue was up 34.5% on a year-over-year basis. During the same period in the prior year, the firm posted $0.80 earnings per share. As a group, research analysts expect that Axon Enterprise, Inc. will post 1.79 EPS for the current fiscal year.

Insider Activity

In related news, Director Jeri Williams sold 110 shares of the firm's stock in a transaction on Monday, September 30th. The stock was sold at an average price of $400.00, for a total value of $44,000.00. Following the completion of the transaction, the director now owns 1,934 shares in the company, valued at $773,600. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. In related news, Director Jeri Williams sold 110 shares of the stock in a transaction that occurred on Monday, September 30th. The shares were sold at an average price of $400.00, for a total value of $44,000.00. Following the transaction, the director now owns 1,934 shares in the company, valued at approximately $773,600. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Patrick W. Smith sold 80,300 shares of Axon Enterprise stock in a transaction that occurred on Friday, August 23rd. The shares were sold at an average price of $371.78, for a total transaction of $29,853,934.00. Following the sale, the chief executive officer now owns 3,015,366 shares of the company's stock, valued at approximately $1,121,052,771.48. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 371,172 shares of company stock valued at $137,000,162 over the last ninety days. 5.70% of the stock is currently owned by insiders.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.